Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Cote

Showing results (151-160 of 213) with videos related to

Pageof 22
Sort By:
Journal of the National Cancer Institute|May 6, 2024
Ataxia telangiectasia and Rad3-related (ATR) inhibitor camonsertib dose optimization in patients with biomarker-selected advanced solid tumors (TRESR study)Elisa Fontana, Ezra Rosen, Elizabeth K Lee, et al.
Cell Reports. Medicine|December 30, 2020
Development and Preliminary Clinical Activity of PD-1-Guided CTLA-4 Blocking Bispecific DART MoleculeAlexey Berezhnoy, Bradley J Sumrow, Kurt Stahl, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|February 14, 2023
Prognostic Significance of Percentage and Size of Dedifferentiation in Dedifferentiated ChondrosarcomaYin P Hung, Ivan Chebib, Miriam A Bredella, et al.
Investigational New Drugs|May 4, 2026
Pooled safety analysis of lurbinectedin plus irinotecan in patients with advanced solid tumorsAlejandro Falcón, Gregory M Cote, Javier Molina-Cerrillo, et al.
Biomedical Microdevices|September 27, 2017
Interventional magnetic resonance imaging guided carotid embolectomy using a novel resonant marker catheter: demonstration of preclinical feasibilityJeffrey K Yang, Andre M Cote, Caroline D Jordan, et al.
Nature Communications|August 28, 2024
EWS-WT1 fusion isoforms establish oncogenic programs and therapeutic vulnerabilities in desmoplastic small round cell tumorsGaylor Boulay, Liliane C Broye, Rui Dong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2025
Milademetan in advanced solid tumors with MDM2 amplification and wild-type TP53: pre-clinical and phase 2 clinical trial resultsEcaterina E Dumbrava, Thomas E Stinchcombe, Mrinal Gounder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 13, 2020
Ivosidenib in Isocitrate Dehydrogenase 1<i>-</i>Mutated Advanced GliomaIngo K Mellinghoff, Benjamin M Ellingson, Mehdi Touat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 19, 2023
Phase II Study of Olaparib and Temozolomide for Advanced Uterine Leiomyosarcoma (NCI Protocol 10250)Matthew Ingham, Jacob B Allred, Li Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2021
Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I TrialIngo K Mellinghoff, Marta Penas-Prado, Katherine B Peters, et al.
Pageof 22

Showing results (151-160 of 213) with videos related to

Sort By:
Pageof 22
Journal of the National Cancer Institute|May 6, 2024
Ataxia telangiectasia and Rad3-related (ATR) inhibitor camonsertib dose optimization in patients with biomarker-selected advanced solid tumors (TRESR study)Elisa Fontana, Ezra Rosen, Elizabeth K Lee, et al.
Cell Reports. Medicine|December 30, 2020
Development and Preliminary Clinical Activity of PD-1-Guided CTLA-4 Blocking Bispecific DART MoleculeAlexey Berezhnoy, Bradley J Sumrow, Kurt Stahl, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|February 14, 2023
Prognostic Significance of Percentage and Size of Dedifferentiation in Dedifferentiated ChondrosarcomaYin P Hung, Ivan Chebib, Miriam A Bredella, et al.
Investigational New Drugs|May 4, 2026
Pooled safety analysis of lurbinectedin plus irinotecan in patients with advanced solid tumorsAlejandro Falcón, Gregory M Cote, Javier Molina-Cerrillo, et al.
Biomedical Microdevices|September 27, 2017
Interventional magnetic resonance imaging guided carotid embolectomy using a novel resonant marker catheter: demonstration of preclinical feasibilityJeffrey K Yang, Andre M Cote, Caroline D Jordan, et al.
Nature Communications|August 28, 2024
EWS-WT1 fusion isoforms establish oncogenic programs and therapeutic vulnerabilities in desmoplastic small round cell tumorsGaylor Boulay, Liliane C Broye, Rui Dong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2025
Milademetan in advanced solid tumors with MDM2 amplification and wild-type TP53: pre-clinical and phase 2 clinical trial resultsEcaterina E Dumbrava, Thomas E Stinchcombe, Mrinal Gounder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 13, 2020
Ivosidenib in Isocitrate Dehydrogenase 1<i>-</i>Mutated Advanced GliomaIngo K Mellinghoff, Benjamin M Ellingson, Mehdi Touat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 19, 2023
Phase II Study of Olaparib and Temozolomide for Advanced Uterine Leiomyosarcoma (NCI Protocol 10250)Matthew Ingham, Jacob B Allred, Li Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2021
Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I TrialIngo K Mellinghoff, Marta Penas-Prado, Katherine B Peters, et al.
Pageof 22